These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 10433170)
1. Effects of gemfibrozil on lipid and hemostatic factors in CAPD patients. Lee MS; Kim SM; Kim SB; Lee SK; Park JS; Yang WS Perit Dial Int; 1999; 19(3):280-3. PubMed ID: 10433170 [No Abstract] [Full Text] [Related]
2. Hemostatic effects of omega-3 fatty acids in isolated hypertriglyceridemic patients treated with bezafibrate. Krysiak R; Okopien B Eur J Intern Med; 2012 Sep; 23(6):e168-9. PubMed ID: 22863446 [No Abstract] [Full Text] [Related]
4. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707 [TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study. Akçiçek F; Ok E; Duman S; Kürsad S; Unsal A; Alev M; Atabay G; Basçi A Adv Perit Dial; 1996; 12():261-5. PubMed ID: 8865916 [TBL] [Abstract][Full Text] [Related]
6. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250 [TBL] [Abstract][Full Text] [Related]
7. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Chan NN; Chow FC Lancet; 2001 Nov; 358(9295):1811; author reply 1811-2. PubMed ID: 11734263 [No Abstract] [Full Text] [Related]
8. Safe use of gemfibrozil in uremic patients on continuous ambulatory peritoneal dialysis. Lucatello A; Sturani A; Di Nardo AM; Cocchi R; Fusaroli M Nephron; 1998; 78(3):338. PubMed ID: 9546699 [No Abstract] [Full Text] [Related]
9. Gemfibrozil lowers plasma lipids and increases polyunsaturated fatty acid content and oxidative susceptibility of lipoproteins in hypertriglyceridemia. Smith WG; Wang J; Dang AQ; Reeves C; Bibbs D; Faas FH Clin Chim Acta; 2002 Aug; 322(1-2):77-84. PubMed ID: 12104084 [TBL] [Abstract][Full Text] [Related]
10. The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group. Avogaro A; Piliego T; Catapano A; Miola M; Tiengo A Acta Diabetol; 1999 Jun; 36(1-2):27-33. PubMed ID: 10436249 [TBL] [Abstract][Full Text] [Related]
20. Effects of fixed low-dose warfarin on hemostatic factors in continuous ambulatory peritoneal dialysis patients. Kim SB; Lee SK; Park JS; Chi HS; Hong CD; Yang WS Am J Kidney Dis; 2001 Feb; 37(2):343-7. PubMed ID: 11157376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]